Insider transactions

EDGAR

Invivyd, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
20 transactions, 455,196 shares
Sum of shares × price per share: 531,320.8594

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 54

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-08-31 Filed 2026-09-02Sheffield Ian Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (100,000) — exercise price 0.9549
Acquired (A)100,0000—100,000Direct (D) No
F1
  • F1 This option was granted on August 31, 2026 and vests over a three-year period, with one-third of the shares subject to the grant vesting on the first anniversary of the grant date and 1/36th of the total shares subject to the grant vesting in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date.
Open filing 0001193125-26-380337 Read from the filing’s XML Dispute this row
2026-08-30 Filed 2026-09-01Elia Marc Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (10,700,000) — exercise price 0.9645
Acquired (A)10,700,0000—10,700,000Direct (D) No
F1
  • F1 This option vests over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the grant date of August 30, 2026 and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.
Open filing 0001193125-26-378862 Read from the filing’s XML Dispute this row
2026-08-18 Filed 2026-08-18Green Julie Officer: Chief Human Resources Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)18,4250.8429
15,530.4325

Derived: shares × price per share. Exact value 15530.4325.

168,937Direct (D) Yes
F2, F4
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.760 to $0.872, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Open filing 0001193125-26-355914 Read from the filing’s XML Dispute this row
2026-08-18 Filed 2026-08-18Duke William E. Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)18,4250.8429
15,530.4325

Derived: shares × price per share. Exact value 15530.4325.

168,937Direct (D) Yes
F2, F4
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.760 to $0.872, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Open filing 0001193125-26-355913 Read from the filing’s XML Dispute this row
2026-08-18 Filed 2026-08-18Lee Timothy Edward Officer: Chief Commercial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)18,4250.8429
15,530.4325

Derived: shares × price per share. Exact value 15530.4325.

178,937Direct (D) Yes
F2, F4
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.760 to $0.872, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Open filing 0001193125-26-355915 Read from the filing’s XML Dispute this row
2026-08-18 Filed 2026-08-18Andersen Jill Officer: Chief Legal Officer, Secretary
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)30,7060.8429
25,882.0874

Derived: shares × price per share. Exact value 25882.0874.

283,774Direct (D) Yes
F2, F4
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.760 to $0.872, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Open filing 0001193125-26-355912 Read from the filing’s XML Dispute this row
2026-08-18 Filed 2026-08-18Allen Robert D. III Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)17,0430.8429
14,365.5447

Derived: shares × price per share. Exact value 14365.5447.

178,765Direct (D) Yes
F2, F4
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.760 to $0.872, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Open filing 0001193125-26-355911 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-18Green Julie Officer: Chief Human Resources Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)22,3550.7220
16,140.31

Derived: shares × price per share. Exact value 16140.3100.

187,362Direct (D) Yes
F2, F3
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.682 to $0.830, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Open filing 0001193125-26-355914 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-18Duke William E. Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)22,3550.7220
16,140.31

Derived: shares × price per share. Exact value 16140.3100.

187,362Direct (D) Yes
F2, F3
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.682 to $0.830, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Open filing 0001193125-26-355913 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-18Lee Timothy Edward Officer: Chief Commercial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)22,3550.7220
16,140.31

Derived: shares × price per share. Exact value 16140.3100.

197,362Direct (D) Yes
F2, F3
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.682 to $0.830, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Open filing 0001193125-26-355915 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-18Andersen Jill Officer: Chief Legal Officer, Secretary
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)37,2560.7220
26,898.832

Derived: shares × price per share. Exact value 26898.8320.

314,480Direct (D) Yes
F2, F3
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.682 to $0.830, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Open filing 0001193125-26-355912 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-18Allen Robert D. III Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)20,6790.7220
14,930.238

Derived: shares × price per share. Exact value 14930.2380.

195,808Direct (D) Yes
F2, F3
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.682 to $0.830, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Open filing 0001193125-26-355911 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-08-18Green Julie Officer: Chief Human Resources Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)102,000——209,717Direct (D) Yes
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
Open filing 0001193125-26-355914 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-08-18Green Julie Officer: Chief Human Resources Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (102,000)
Disposed (D)102,0000—0Direct (D) Yes
F1, F5
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
  • F5 This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date.
Open filing 0001193125-26-355914 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-08-18Duke William E. Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)102,000——209,717Direct (D) Yes
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
Open filing 0001193125-26-355913 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-08-18Duke William E. Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (102,000)
Disposed (D)102,0000.00
0

Derived: shares × price per share. Exact value 0.00.

0Direct (D) Yes
F1, F5
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
  • F5 This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date.
Open filing 0001193125-26-355913 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-08-18Lee Timothy Edward Officer: Chief Commercial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)102,000——219,717Direct (D) Yes
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
Open filing 0001193125-26-355915 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-08-18Lee Timothy Edward Officer: Chief Commercial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (102,000)
Disposed (D)102,0000.00
0

Derived: shares × price per share. Exact value 0.00.

0Direct (D) Yes
F1, F5
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
  • F5 This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date.
Open filing 0001193125-26-355915 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-08-18Andersen Jill Officer: Chief Legal Officer, Secretary
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)170,000——351,736Direct (D) Yes
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
Open filing 0001193125-26-355912 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-08-18Andersen Jill Officer: Chief Legal Officer, Secretary
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (170,000)
Disposed (D)170,0000.00
0

Derived: shares × price per share. Exact value 0.00.

0Direct (D) Yes
F1, F5
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
  • F5 This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date.
Open filing 0001193125-26-355912 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-08-18Allen Robert D. III Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)102,000——216,487Direct (D) Yes
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
Open filing 0001193125-26-355911 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-08-18Allen Robert D. III Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (102,000)
Disposed (D)102,0000.00
0

Derived: shares × price per share. Exact value 0.00.

0Direct (D) Yes
F1, F5
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
  • F5 This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date.
Open filing 0001193125-26-355911 Read from the filing’s XML Dispute this row
2026-07-31 Filed 2026-08-04Mina Michael Officer: CMO and Chief Epidemiologist
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (1,125,000) — exercise price 0.535
Acquired (A)1,125,0000—1,125,000Direct (D) No
F1
  • F1 This option vests over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the grant date of July 31, 2026 and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.
Open filing 0001193125-26-332844 Read from the filing’s XML Dispute this row
2026-05-19 Filed 2026-05-21Elia Marc Director · Other: See RemarksM28 Capital Management LP Other: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (50,000) — exercise price 1.04
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date. The grant was awarded to Marc Elia (Mr. Elia). Mr. Elia is deemed to hold the grant for the benefit of M28 Capital Management LP (M28 Capital Management) and the funds managed by M28 Capital Management.
Open filing 0001193125-26-234661 Read from the filing’s XML Dispute this row
2026-05-19 Filed 2026-05-21Royan Ajay Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (50,000) — exercise price 1.04
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001193125-26-234666 Read from the filing’s XML Dispute this row
2026-05-19 Filed 2026-05-21MCGUIRE TERRANCE Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (50,000) — exercise price 1.04
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001193125-26-234662 Read from the filing’s XML Dispute this row
2026-05-19 Filed 2026-05-21BOLNO PAUL Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (32,876) — exercise price 1.04
Acquired (A)32,8760—32,876Direct (D) No
F1
  • F1 This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001193125-26-234660 Read from the filing’s XML Dispute this row
2026-05-19 Filed 2026-05-21MCLAUGHLIN KEVIN F Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (50,000) — exercise price 1.04
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001193125-26-234665 Read from the filing’s XML Dispute this row
2026-05-19 Filed 2026-05-21Berry Tamsin Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (50,000) — exercise price 1.04
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.
Open filing 0001193125-26-234656 Read from the filing’s XML Dispute this row
2026-02-18 Filed 2026-02-18Green Julie Officer: Chief Human Resources Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)20,9641.5778
33,076.9992

Derived: shares × price per share. Exact value 33076.9992.

107,717Direct (D) Yes
F2, F4
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.550 to $1.595, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Open filing 0001193125-26-057822 Read from the filing’s XML Dispute this row
2026-02-18 Filed 2026-02-18Andersen Jill Officer: Chief Legal Officer, Secretary
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)34,9391.5778
55,126.7542

Derived: shares × price per share. Exact value 55126.7542.

181,736Direct (D) Yes
F2, F4
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.550 to $1.595, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Open filing 0001193125-26-057814 Read from the filing’s XML Dispute this row
2026-02-18 Filed 2026-02-18Lee Timothy Edward Officer: Chief Commercial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)20,9641.5778
33,076.9992

Derived: shares × price per share. Exact value 33076.9992.

117,717Direct (D) Yes
F3, F5
  • F3 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.550 to $1.595, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
Open filing 0001193125-26-057815 Read from the filing’s XML Dispute this row
2026-02-18 Filed 2026-02-18Allen Robert D. III Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)19,3921.5778
30,596.6976

Derived: shares × price per share. Exact value 30596.6976.

114,487Direct (D) Yes
F2, F4
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.550 to $1.595, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Open filing 0001193125-26-057828 Read from the filing’s XML Dispute this row
2026-02-18 Filed 2026-02-18Duke William E. Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)20,9641.5778
33,076.9992

Derived: shares × price per share. Exact value 33076.9992.

107,717Direct (D) Yes
F2, F4
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.550 to $1.595, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Open filing 0001193125-26-057819 Read from the filing’s XML Dispute this row
2026-02-17 Filed 2026-02-18Green Julie Officer: Chief Human Resources Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)19,6631.5396
30,273.1548

Derived: shares × price per share. Exact value 30273.1548.

128,681Direct (D) Yes
F2, F3
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.505 to $1.590, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Open filing 0001193125-26-057822 Read from the filing’s XML Dispute this row
2026-02-17 Filed 2026-02-18Andersen Jill Officer: Chief Legal Officer, Secretary
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)32,7711.5396
50,454.2316

Derived: shares × price per share. Exact value 50454.2316.

216,675Direct (D) Yes
F2, F3
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.505 to $1.590, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Open filing 0001193125-26-057814 Read from the filing’s XML Dispute this row
2026-02-17 Filed 2026-02-18Lee Timothy Edward Officer: Chief Commercial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)19,6631.5396
30,273.1548

Derived: shares × price per share. Exact value 30273.1548.

138,681Direct (D) Yes
F3, F4
  • F3 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.505 to $1.590, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Open filing 0001193125-26-057815 Read from the filing’s XML Dispute this row
2026-02-17 Filed 2026-02-18Allen Robert D. III Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)18,1891.5396
28,003.7844

Derived: shares × price per share. Exact value 28003.7844.

133,879Direct (D) Yes
F2, F3
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.505 to $1.590, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Open filing 0001193125-26-057828 Read from the filing’s XML Dispute this row
2026-02-17 Filed 2026-02-18Duke William E. Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)19,6631.5396
30,273.1548

Derived: shares × price per share. Exact value 30273.1548.

128,681Direct (D) Yes
F2, F3
  • F2 The sales reported on this Form 4 represent shares sold to satisfy the Reporting Person's tax withholding obligations upon vesting of an RSU award in non-discretionary sell-to-cover transactions pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 20, 2025.
  • F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.505 to $1.590, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the U.S. Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Open filing 0001193125-26-057819 Read from the filing’s XML Dispute this row
2026-02-15 Filed 2026-02-18Green Julie Officer: Chief Human Resources Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)99,000——148,344Direct (D) Yes
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
Open filing 0001193125-26-057822 Read from the filing’s XML Dispute this row
2026-02-15 Filed 2026-02-18Green Julie Officer: Chief Human Resources Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (99,000)
Disposed (D)99,0000.00
0

Derived: shares × price per share. Exact value 0.00.

102,000Direct (D) Yes
F1, F5
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
  • F5 This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date.
Open filing 0001193125-26-057822 Read from the filing’s XML Dispute this row
2026-02-15 Filed 2026-02-18Andersen Jill Officer: Chief Legal Officer, Secretary
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)165,000——249,446Direct (D) Yes
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
Open filing 0001193125-26-057814 Read from the filing’s XML Dispute this row
2026-02-15 Filed 2026-02-18Andersen Jill Officer: Chief Legal Officer, Secretary
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (165,000)
Disposed (D)165,0000.00
0

Derived: shares × price per share. Exact value 0.00.

170,000Direct (D) Yes
F1, F5
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
  • F5 This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date.
Open filing 0001193125-26-057814 Read from the filing’s XML Dispute this row
2026-02-15 Filed 2026-02-18Lee Timothy Edward Officer: Chief Commercial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)99,000——158,344Direct (D) Yes
F1, F2
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
  • F2 The reported ownership includes 10,000 shares of common stock acquired through the Company's Employee Stock Purchase Program.
Open filing 0001193125-26-057815 Read from the filing’s XML Dispute this row
2026-02-15 Filed 2026-02-18Lee Timothy Edward Officer: Chief Commercial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (99,000)
Disposed (D)99,0000—102,000Direct (D) Yes
F1, F6
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
  • F6 This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date.
Open filing 0001193125-26-057815 Read from the filing’s XML Dispute this row
2026-02-15 Filed 2026-02-18Allen Robert D. III Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)99,000——152,068Direct (D) Yes
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
Open filing 0001193125-26-057828 Read from the filing’s XML Dispute this row
2026-02-15 Filed 2026-02-18Allen Robert D. III Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (99,000)
Disposed (D)99,0000—102,000Direct (D) Yes
F1, F5
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
  • F5 This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date.
Open filing 0001193125-26-057828 Read from the filing’s XML Dispute this row
2026-02-15 Filed 2026-02-18Duke William E. Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)99,000——148,344Direct (D) Yes
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
Open filing 0001193125-26-057819 Read from the filing’s XML Dispute this row
2026-02-15 Filed 2026-02-18Duke William E. Officer: Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (99,000)
Disposed (D)99,0000.00
0

Derived: shares × price per share. Exact value 0.00.

102,000Direct (D) Yes
F1, F5
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of Invivyd, Inc. (the Company).
  • F5 This RSU award vests over an eighteen-month period, with one-third of the RSUs vesting every six months following the grant date of February 15, 2025, subject to the Reporting Person's continuous service as of each vesting date.
Open filing 0001193125-26-057819 Read from the filing’s XML Dispute this row
2026-01-29 Filed 2026-01-30Lee Timothy Edward Officer: Chief Commercial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (675,000) — exercise price 1.85
Acquired (A)675,0000.00
0

Derived: shares × price per share. Exact value 0.00.

675,000Direct (D) No
F1
  • F1 This option vests over a three-year period, with 1/36th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date of January 29, 2026, subject to the Reporting Person's continuous service as of each vesting date.
Open filing 0001193125-26-031840 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Perceptive Advisors LLC Common Stock, $0.0001 par value per share4.713,762,63709/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-463811 Dispute this row
Joseph Edelman Common Stock, $0.0001 par value per share4.713,762,63709/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-463811 Dispute this row
Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.0001 par value per share4.713,762,63709/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-463811 Dispute this row
Maverick Capital, Ltd. Common Stock, $0.0001 par value per share8.324,442,16009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-001059 Dispute this row
Maverick Capital Management, LLC Common Stock, $0.0001 par value per share8.324,442,16009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-001059 Dispute this row
Lee S. Ainslie III Common Stock, $0.0001 par value per share8.324,442,16009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 4Open filing 0001012975-26-001059 Dispute this row
Perceptive Advisors LLC Common Stock, $0.0001 par value per share6.318,490,63606/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-352642 Dispute this row
Joseph Edelman Common Stock, $0.0001 par value per share6.318,490,63606/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-352642 Dispute this row
Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.0001 par value per share6.318,490,63606/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-352642 Dispute this row
BIOTECHNOLOGY VALUE FUND L P Common Stock, $0.0001 par value per share5.416,031,969.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-002171 Dispute this row
BVF I GP LLC Common Stock, $0.0001 par value per share5.416,031,969.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-002171 Dispute this row
BIOTECHNOLOGY VALUE FUND II LP Common Stock, $0.0001 par value per share3.811,183,991.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-002171 Dispute this row
BVF II GP LLC Common Stock, $0.0001 par value per share3.811,183,991.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-002171 Dispute this row
Biotechnology Value Trading Fund OS LP Common Stock, $0.0001 par value per share0.61,887,918.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-002171 Dispute this row
BVF Partners OS Ltd. Common Stock, $0.0001 par value per share0.61,887,918.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-002171 Dispute this row
BVF GP HOLDINGS LLC Common Stock, $0.0001 par value per share9.227,215,960.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-002171 Dispute this row
BVF PARTNERS L P/IL Common Stock, $0.0001 par value per share9.9929,571,826.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-002171 Dispute this row
BVF INC/IL Common Stock, $0.0001 par value per share9.9929,571,826.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-002171 Dispute this row
LAMPERT MARK N Common Stock, $0.0001 par value per share9.9929,571,826.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000921895-26-002171 Dispute this row
BlackRock, Inc. Common Stock5.516,124,69606/30/2026 Filed 2026-07-28SCHEDULE 13GOpen filing 0002012383-26-002467 Dispute this row
Point72 Asset Management, L.P. Common Stock, par value $0.0001 per share043,931.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 3Open filing 0000919574-26-003489 Dispute this row
Point72 Capital Advisors, Inc. Common Stock, par value $0.0001 per share043,931.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 3Open filing 0000919574-26-003489 Dispute this row
Steven A. Cohen Common Stock, par value $0.0001 per share043,931.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 3Open filing 0000919574-26-003489 Dispute this row
RA Capital Management, L.P. Common Stock, $0.0001 par value per share7.021,342,442.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001346824-26-000155 Dispute this row
Peter Kolchinsky Common Stock, $0.0001 par value per share7.021,342,442.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001346824-26-000155 Dispute this row
Rajeev Shah Common Stock, $0.0001 par value per share7.021,342,442.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001346824-26-000155 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, $0.0001 par value per share7.021,342,442.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001346824-26-000155 Dispute this row
Point72 Asset Management, L.P. Common Stock, par value $0.0001 per share6.016,653,036.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0000902664-26-001128 Dispute this row
Point72 Capital Advisors, Inc. Common Stock, par value $0.0001 per share6.016,653,036.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0000902664-26-001128 Dispute this row
Steven A. Cohen Common Stock, par value $0.0001 per share6.016,653,036.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0000902664-26-001128 Dispute this row
BIOTECHNOLOGY VALUE FUND L P Common Stock, $0.0001 par value per share4.913,619,218.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-000469 Dispute this row
BVF I GP LLC Common Stock, $0.0001 par value per share4.913,619,218.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-000469 Dispute this row
BIOTECHNOLOGY VALUE FUND II LP Common Stock, $0.0001 par value per share3.69,954,397.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-000469 Dispute this row
BVF II GP LLC Common Stock, $0.0001 par value per share3.69,954,397.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-000469 Dispute this row
Biotechnology Value Trading Fund OS LP Common Stock, $0.0001 par value per share0.61,563,852.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-000469 Dispute this row
BVF Partners OS Ltd. Common Stock, $0.0001 par value per share0.61,563,852.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-000469 Dispute this row
BVF GP HOLDINGS LLC Common Stock, $0.0001 par value per share8.323,573,615.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-000469 Dispute this row
BVF PARTNERS L P/IL Common Stock, $0.0001 par value per share9.025,525,000.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-000469 Dispute this row
BVF INC/IL Common Stock, $0.0001 par value per share9.025,525,000.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-000469 Dispute this row
LAMPERT MARK N Common Stock, $0.0001 par value per share9.025,525,000.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0000921895-26-000469 Dispute this row
RA Capital Management, L.P. Common Stock, $0.0001 par value per share9.928,857,208.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001346824-26-000045 Dispute this row
Peter Kolchinsky Common Stock, $0.0001 par value per share9.928,857,208.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001346824-26-000045 Dispute this row
Rajeev Shah Common Stock, $0.0001 par value per share9.928,857,208.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001346824-26-000045 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, $0.0001 par value per share9.928,857,208.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001346824-26-000045 Dispute this row
Maverick Capital, Ltd. Common Stock, $0.0001 par value per share6.718,970,91312/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 3Open filing 0001012975-26-000135 Dispute this row
Maverick Capital Management, LLC Common Stock, $0.0001 par value per share6.718,970,91312/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 3Open filing 0001012975-26-000135 Dispute this row
Lee S. Ainslie III Common Stock, $0.0001 par value per share6.718,970,91312/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 3Open filing 0001012975-26-000135 Dispute this row
Soleus Private Equity Fund III, L.P. Common Stock, par value $0.0001 per share0.61,680,160.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-015651 Dispute this row
Soleus Private Equity GP III, LLC Common Stock, par value $0.0001 per share0.61,680,160.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-015651 Dispute this row
Soleus PE GP III, LLC Common Stock, par value $0.0001 per share0.61,680,160.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-015651 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,715,586 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015131,968
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to Invivyd, Inc.